Appendix A
Public Meeting Agendas
FIRST PUBLIC MEETING
January 28, 2019
National Academy of Sciences Building
2101 Constitution Avenue, NW
Washington, DC 20001
Board Room
1:00–1:10 p.m. ET | Welcome and introductions; Conduct of the Open Session David Savitz, Ph.D., Committee Chair |
1:10–1:50 p.m. | Charge to the Committee Peter R. Rumm, M.D., M.P.H., Director, Pre-9/11 Era Environmental Health Program, Department of Veterans Affairs, with Dr. R. Loren Erickson, Chief Consultant, Post Deployment Health |
1:50–2:20 p.m. | Overview of Antimalarials Use Policy and Monitoring in Service Members COL Andrew Wiesen, M.D., M.P.H., Director, Preventive Medicine, Health Readiness Policy and Oversight, Office of the Assistant Secretary of Defense (Health Affairs) |
2:20–2:50 p.m. | Food and Drug Administration Adverse Events Reporting System Kelly Yoojung Cao, Pharm.D., Team Leader, Division of Pharmacovigilance II, Food and Drug Administration |
2:50–3:30 p.m. | Centers for Disease Control and Prevention Monitoring of Malaria and Research Related to Antimalarials Use Kathrine Tan, M.D., M.P.H., Chief, Domestic Response Unit, Malaria Branch, Centers for Disease Control and Prevention |
3:30–3:50 p.m. | Identifying and Evaluating Sources of Evidence of Quinism: A Novel Disease Affecting U.S. Veterans Remington Nevin, M.D., M.P.H., Dr.P.H., Executive Director, The Quinism Foundation |
3:50–4:20 p.m.1 | Public Comments Limited to 3 minutes per individual/organization |
4:20 p.m. | OPEN SESSION ENDS |
_______________
1 To be extended if needed to accommodate those wishing to make a public statement.
SECOND PUBLIC MEETING AGENDA
March 27, 2019
OPEN SESSION
Keck Building
500 Fifth Street, NW, Washington, DC
Keck Room 105
9:30–9:35 a.m. ET | Welcome and Introductions; Conduct of the Open Session David Savitz, Ph.D., Committee Chair |
9:35–10:05 a.m. | Overview of Antimalarials Use Policy and Monitoring in Peace Corps Volunteers Kyle Petersen, D.O, F.I.D.S.A., F.A.C.P., Director of Epidemiology, Peace Corps |
10:05–10:25 a.m. | Antimalarials—Use Policy and Monitoring in Deployed Employees of Department of State Kim Ottwell, M.D., Clinical Director of Clinical Services |
10:25–11:25 a.m. | Neurotoxic Mechanisms of Antimalarials Thomas Brewer, M.D., University of Washington, and Principle, Global Enterics, LLC |
11:25–11:50 a.m. | Public Comments Limited to 3 minutes per individual/organization |
11:50 a.m. | OPEN SESSION ENDS |
This page intentionally left blank.